FDG-PET Keeps Myocardial Viability at the Center of Ischemic Cardiomyopathy Care
Assessment of myocardial viability remains central in patients with ischemic cardiomyopathy and left ventricular dysfunction because the question is not simply whether myocardium is injured, but whether any of it can still recover after revascularization. Fluorine-18 fluorodeoxyglucose PET remains the reference standard for identifying dysfunctional yet metabolically active tissue, separating scar from hibernating myocardium with a level of biologic specificity that anatomic imaging alone cannot provide. In practical terms, the scan addresses a bedside decision that continues to shape care: whether to pursue revascularization in a ventricle that looks weak but may still contain salvageable muscle.
Viability imaging sits at the intersection of perfusion, metabolism, and contractile dysfunction. Chronically underperfused myocardium can downshift from normal oxidative metabolism to glucose utilization, preserving cell survival while sacrificing mechanical performance. FDG-PET exploits this shift by mapping glucose uptake in myocardium that no longer contracts normally; regions with preserved uptake despite reduced wall motion are the classic signature of hibernating but potentially recoverable tissue. The biological logic is straightforward, and so is the clinical consequence: when viable myocardium is present, restoring blood flow can improve function, symptoms, and selection for intervention.
Why Metabolic Imaging Outperforms Contractile Assessment Alone
Echocardiography, single-photon techniques, and coronary anatomy each answer a different question, but none fully resolves tissue-level viability. A dysfunctional segment may be scarred, stunned, hibernating, or simply underloaded at the time of assessment. FDG-PET focuses on metabolism, which makes it uniquely useful when contractile reserve is absent or equivocal. By identifying myocardium that remains metabolically alive, the technique helps clinicians avoid treating irreversible scar as though it were still recoverable tissue.
The review emphasizes that viability assessment is not an academic exercise. In ischemic cardiomyopathy, the decision to revascularize carries meaningful procedural risk, especially when ventricular function is poor and coronary disease is extensive. Metabolic imaging helps define whether that risk may be justified by a realistic chance of functional recovery. In patients with diffuse dysfunction, the presence of viable segments can change the balance between medical therapy alone and a more aggressive revascularization strategy.
A scar does not recover because blood flow improves.
Imaging Protocols Shape the Signal as Much as the Biology
FDG-PET depends on careful preparation because the heart is metabolically flexible and substrate selection varies widely with fasting state, insulin resistance, diabetes, and recent food intake. Image quality and interpretability depend on suppressing normal myocardial fatty acid use and encouraging glucose uptake in viable tissue. Protocols therefore matter as much as scanner capability, and they are integral to the diagnostic yield of the test. Poor preparation can blur the distinction between true metabolic defect and physiologic variation, especially in patients with diabetes or advanced heart failure.
Interpretation also requires pairing FDG metabolism with perfusion information. The classic viability pattern is preserved or relatively preserved FDG uptake in a segment with reduced perfusion and impaired contraction. This mismatch points toward hibernating myocardium rather than transmural scar. When both perfusion and FDG uptake are severely reduced, the tissue is far less likely to recover. The clinical value of the method lies in these pattern-based distinctions, which translate directly into revascularization planning.
Hybrid PET/computed tomography and PET/MR systems extend that interpretive framework by adding anatomic and functional context. These platforms can refine localization, reduce ambiguity, and help integrate viability data with coronary anatomy, scar burden, and ventricular remodeling. For patients with multivessel disease or prior infarction, that combined view can be particularly useful when procedural decisions hinge on whether the left ventricle still contains recoverable territory.
Quantification, AI, and Radiomics Are Changing How Viability Is Measured
The review places strong emphasis on newer technical advances that move viability imaging beyond visual readout alone. Quantitative approaches can standardize tracer uptake assessment and reduce reliance on purely qualitative interpretation. As scanners and reconstruction methods improve, the field is moving toward more reproducible measures of myocardial glucose handling, making comparisons across patients and over time more reliable.
Artificial intelligence and radiomics add another layer. These tools can extract patterns from images that are difficult to appreciate by eye, potentially improving detection of subtle metabolic heterogeneity, segment-level viability, and relationships between uptake and remodeling. In ischemic cardiomyopathy, where partial viability can coexist with dense scar and chronic stunning, automated pattern recognition may help refine patient selection and prognostication. The promise is not merely faster reporting; it is more consistent interpretation of complex biologic signals.
Emerging molecular tracers broaden the scope even further. FDG has long occupied the center of viability imaging, but newer tracers may help address questions that FDG alone cannot fully answer, including inflammatory activity, fibrosis, or alternative metabolic states. Those developments could eventually expand viability assessment from a binary alive-or-dead framework into a more nuanced tissue characterization strategy.
What the Evidence Means at the Bedside
FDG-PET remains clinically relevant because ischemic cardiomyopathy is not a uniform disease. Some patients have mostly irreversible scar, while others harbor enough living myocardium to justify revascularization despite severe dysfunction. The scan helps distinguish those groups with metabolic evidence rather than assumption. In a field where treatment decisions can carry major consequences for symptoms, function, and procedural exposure, that distinction remains indispensable.
The technique also has limits that are hard to ignore. Image interpretation depends on protocol quality, patient preparation, and access to advanced imaging infrastructure. Diabetes, insulin resistance, and altered substrate metabolism can complicate acquisition and analysis. Even when viability is demonstrated, the result does not guarantee recovery after revascularization, because outcome also depends on coronary anatomy, completeness of revascularization, myocardial scar burden, and the broader hemodynamic state of the patient.
These constraints do not diminish the role of FDG-PET; they define how carefully it must be used. The strongest use case remains the patient with ischemic left ventricular dysfunction in whom the presence or absence of viable myocardium could alter the entire treatment pathway. For those patients, metabolic imaging remains one of the most biologically grounded tools in cardiovascular imaging.
Where Viability Imaging Still Needs Better Answers
Persistent challenges remain in standardization, availability, and interpretation across institutions. Protocol heterogeneity can limit comparability, and the field still needs clearer alignment on how quantitative thresholds should guide real-world decisions. Hybrid imaging and AI may improve reproducibility, but they also introduce new questions about validation, workflow integration, and the degree to which automated outputs should influence intervention decisions.
The next phase of viability imaging will likely depend on whether newer tracers and quantitative workflows can deliver practical gains without sacrificing the physiologic clarity that made FDG-PET the standard in the first place. For now, the method remains anchored in a simple and clinically consequential principle: dysfunctional myocardium is not always dead, and the ability to identify living tissue still matters when the ventricle looks most exhausted.